| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
2,506,667 |
$27,523,203 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
2,094,650 |
$22,999,257 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Actuate Co-Invest II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
1,259,427 |
$13,828,508 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Clinical Opportunity Fund, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
980,433 |
$10,765,154 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
573,394 |
$6,295,866 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Actuate Co-Invest III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
525,797 |
$5,773,251 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
404,814 |
$4,444,857 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund III NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
383,791 |
$4,214,025 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
307,538 |
$3,376,767 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund I QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
300,749 |
$3,302,224 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Actuate Co-Invest I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
300,143 |
$3,295,570 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
131,248 |
$1,441,103 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
196,428 |
$1,374,996 |
$7.00 |
27 Jun 2025 |
Directly held by Bios 2024 Co-Invest, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
84,917 |
$932,388 |
$10.98 |
27 Jun 2025 |
Directly held by BP Directors, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
69,375 |
$761,737 |
$10.98 |
27 Jun 2025 |
Directly held by Circle K Invesco, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
60,973 |
$669,483 |
$10.98 |
27 Jun 2025 |
Directly held by Aaron G.L. Fletcher |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
8,056 |
$88,454 |
$10.98 |
27 Jun 2025 |
Directly held by KF Legacy Trust U/A/D December 7, 2016 |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
8,056 |
$88,454 |
$10.98 |
27 Jun 2025 |
Directly held by MF Legacy Trust U/A/D December 7, 2016 |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
71,428 |
|
|
27 Jun 2025 |
Directly held by Bios 2024 Co-Invest, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Stock Options |
31,884 |
|
|
12 Aug 2024 |
Directly held by BP Directors, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Stock Options |
15,000 |
|
|
12 Aug 2024 |
Directly held by Aaron G.L. Fletcher |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Convertible Note |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Clinical Opportunity Fund, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series A Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series A Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund I QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Actuate Co-Invest I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Actuate Co-Invest I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Actuate Co-Invest II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund III NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Actuate Co-Invest III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund III NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II QP, LP |